{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T00:36:18Z","timestamp":1793147778360,"version":"4.5.0"},"reference-count":84,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T00:00:00Z","timestamp":1694736000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: CardioOncology"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.jaccao.2023.09.002","type":"journal-article","created":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T15:54:46Z","timestamp":1697558086000},"page":"570-590","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":129,"title":["Cardiovascular Toxicities of BTK\u00a0Inhibitors in Chronic Lymphocytic\u00a0Leukemia"],"prefix":"10.1016","volume":"5","author":[{"given":"Cooper","family":"Quartermaine","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7205-1427","authenticated-orcid":false,"given":"Sanam M.","family":"Ghazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aneeq","family":"Yasin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farrukh T.","family":"Awan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8352-8975","authenticated-orcid":false,"given":"Michael","family":"Fradley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracy","family":"Wiczer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sujay","family":"Kalathoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mussammat","family":"Ferdousi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6067-0506","authenticated-orcid":false,"given":"Satyam","family":"Krishan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alma","family":"Habib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adnan","family":"Shaaban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Onaopepo","family":"Kola-Kehinde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam S.","family":"Kittai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerry A.","family":"Rogers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Grever","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Ruz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seema","family":"Bhat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tyler","family":"Dickerson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John C.","family":"Byrd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Woyach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Addison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaccao.2023.09.002_bib1","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1215637","article-title":"Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia","volume":"369","author":"Byrd","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaccao.2023.09.002_bib2","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1812836","article-title":"Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL","volume":"379","author":"Woyach","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaccao.2023.09.002_bib3","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1509981","article-title":"Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia","volume":"374","author":"Byrd","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaccao.2023.09.002_bib4","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1182\/blood.2020006844","article-title":"A\u00a0randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenstr\u00f6m macroglobulinemia: the ASPEN study","volume":"136","author":"Tam","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.jaccao.2023.09.002_bib5","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1200\/JCO.21.01210","article-title":"Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase III trial","volume":"39","author":"Byrd","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.jaccao.2023.09.002_bib6","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJMoa2211582","article-title":"Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia","volume":"388","author":"Brown","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaccao.2023.09.002_bib7","first-page":"17","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA A Cancer J Clinicians"},{"key":"10.1016\/j.jaccao.2023.09.002_bib9","first-page":"S4","article-title":"Tyrosine kinase inhibitor associated polymorphic ventricular tachycardia","volume":"4","author":"Fazal","year":"2022","journal-title":"J\u00a0Am Coll Cardiol CardioOnc"},{"issue":"1","key":"10.1016\/j.jaccao.2023.09.002_bib10","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s13045-022-01302-7","article-title":"Hypertension and incident cardiovascular events after next-generation BTKi therapy initiation","volume":"15","author":"Chen","year":"2022","journal-title":"J\u00a0Hematol Oncol"},{"key":"10.1016\/j.jaccao.2023.09.002_bib11","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1182\/bloodadvances.2017009720","article-title":"Cumulative incidence, risk factors, and management of atrial fibrillation in patients receiving ibrutinib","volume":"1","author":"Wiczer","year":"2017","journal-title":"Blood Adv"},{"key":"10.1016\/j.jaccao.2023.09.002_bib12","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1182\/blood.2022016953","article-title":"Ventricular arrhythmias and sudden death events following acalabrutinib initiation","volume":"140","author":"Bhat","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.jaccao.2023.09.002_bib13","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.3324\/haematol.2021.278901","article-title":"Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: pooled analysis of 762 patients","volume":"107","author":"Brown","year":"2022","journal-title":"Haematologica"},{"key":"10.1016\/j.jaccao.2023.09.002_bib14","doi-asserted-by":"crossref","DOI":"10.1136\/openhrt-2019-001049","article-title":"High incidence of atrial fibrillation in patients treated with ibrutinib","volume":"6","author":"Baptiste","year":"2019","journal-title":"Open Heart"},{"key":"10.1016\/j.jaccao.2023.09.002_bib15","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.3324\/haematol.2017.171041","article-title":"Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials","volume":"102","author":"Brown","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.jaccao.2023.09.002_bib16","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1182\/blood-2020-137800","article-title":"Evaluation of the incidence and risk factors associated with major cardiovascular events in patients receiving acalabrutinib therapy","volume":"136","author":"Azali","year":"2020","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.jaccao.2023.09.002_bib17","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1080\/10428194.2018.1533129","article-title":"Leukemia & lymphoma risk factors for the development of atrial fibrillation on ibrutinib treatment risk factors for the development of atrial fibrillation on ibrutinib treatment","volume":"60","author":"Lentz","year":"2019","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jaccao.2023.09.002_bib18","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s40959-021-00125-8","article-title":"Pre-existing cardiovascular disease increases risk of atrial arrhythmia and mortality in cancer patients treated with Ibrutinib","volume":"7","author":"Avalon","year":"2021","journal-title":"Cardio-Oncology"},{"key":"10.1016\/j.jaccao.2023.09.002_bib19","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1182\/blood.2019000840","article-title":"Hypertension and incident cardiovascular events following ibrutinib initiation","volume":"134","author":"Dickerson","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jaccao.2023.09.002_bib20","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1161\/CIRCULATIONAHA.120.049210","article-title":"Ibrutinib-mediated atrial fibrillation attributable to inhibition of C-terminal Src kinase","volume":"142","author":"Xiao","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.jaccao.2023.09.002_bib21","doi-asserted-by":"crossref","first-page":"998","DOI":"10.2353\/ajpath.2009.090126","article-title":"Reduced phosphoinositide 3-kinase (p110\u03b1) activation increases the susceptibility to atrial fibrillation","volume":"175","author":"Pretorius","year":"2009","journal-title":"Am J Pathol"},{"issue":"22","key":"10.1016\/j.jaccao.2023.09.002_bib22","article-title":"Distinct effects of ibrutinib and acalabrutinib on mouse atrial and sinoatrial node electrophysiology and arrhythmogenesis","volume":"10","author":"Tuomi","year":"2021","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.jaccao.2023.09.002_bib23","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/j.hrthm.2019.04.008","article-title":"Ibrutinib promotes atrial fibrillation by inducing structural remodeling and calcium dysregulation in the atrium","volume":"16","author":"Jiang","year":"2019","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.jaccao.2023.09.002_bib24","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s00277-020-04094-3","article-title":"Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib: risk prediction, management, and clinical outcomes","volume":"100","author":"Archibald","year":"2021","journal-title":"Ann Hematol"},{"issue":"1_Sup","key":"10.1016\/j.jaccao.2023.09.002_bib25","article-title":"Risks of serious cardiovascular events with next generation BTK inhibitors","author":"Buck","year":"2023","journal-title":"J\u00a0Am Coll Cardiol CardioOnc"},{"key":"10.1016\/j.jaccao.2023.09.002_bib26","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/S0140-6736(21)00224-5","article-title":"Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1\/2 study","volume":"397","author":"Mato","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jaccao.2023.09.002_bib27","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2021-147599","article-title":"Pirtobrutinib, a next generation, highly selective, non-covalent BTK inhibitor in previously treated CLL\/SLL: updated results from the Phase 1\/2 BRUIN Study","volume":"138","author":"Mato","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jaccao.2023.09.002_bib28","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/echo.14946","article-title":"Utilizing left atrial strain to identify patients at risk for atrial fibrillation on ibrutinib","volume":"38","author":"Singh","year":"2021","journal-title":"Echocardiography"},{"key":"10.1016\/j.jaccao.2023.09.002_bib29","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1182\/bloodadvances.2021005621","article-title":"Pooled safety analysis of zanubrutinib monotherapy in patients with B-cell malignancies","volume":"6","author":"Tam","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.jaccao.2023.09.002_bib30","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.7326\/M22-0511","article-title":"Comparative effectiveness and safety between apixaban, dabigatran, edoxaban, and rivaroxaban among patients with atrial fibrillation: a multinational population-based cohort study","volume":"175","author":"Lau","year":"2022","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jaccao.2023.09.002_bib31","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.116.003725","article-title":"Effectiveness and safety of dabigatran, rivaroxaban, and apixaban versus warfarin in nonvalvular atrial fibrillation","volume":"5","author":"Yao","year":"2016","journal-title":"JAHA"},{"key":"10.1016\/j.jaccao.2023.09.002_bib32","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1182\/blood-2016-10-742437","article-title":"Ventricular arrhythmias and sudden death in patients taking ibrutinib","volume":"129","author":"Lampson","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jaccao.2023.09.002_bib33","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.jacc.2018.06.002","article-title":"Ventricular arrhythmias following ibrutinib initiation for lymphoid malignancies","volume":"72","author":"Guha","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jaccao.2023.09.002_bib34","unstructured":"Janssen Updates Warnings Section of Imbruvica Label. 2022. https:\/\/www.formularywatch.com\/view\/janssen-updates-warnings-section-of-imbruvica-label. An access date, if required would be August 1, 2023."},{"issue":"4","key":"10.1016\/j.jaccao.2023.09.002_bib35","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1001\/jamaoncol.2022.6869","article-title":"Cardiovascular magnetic resonance imaging in patients with ibrutinib-associated cardiotoxicity","volume":"9","author":"Buck","year":"2023","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jaccao.2023.09.002_bib36","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1007\/s00280-017-3471-x","article-title":"Ibrutinib does not prolong the corrected QT interval in healthy subjects: results from a thorough QT study","volume":"80","author":"de Jong","year":"2017","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.jaccao.2023.09.002_bib37","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2023.1190099","article-title":"Ibrutinib impairs IGF-1-dependent activation of intracellular Ca handling in isolated mouse ventricular myocytes","volume":"10","author":"Tarnowski","year":"2023","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.jaccao.2023.09.002_bib38","first-page":"238","article-title":"Hypertension in cancer patients and survivors","volume":"1","author":"Cohen","year":"2019","journal-title":"J\u00a0Am Coll Cardiol CardioOnc"},{"key":"10.1016\/j.jaccao.2023.09.002_bib39","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","article-title":"Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia","volume":"373","author":"Burger","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaccao.2023.09.002_bib40","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1400376","article-title":"Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia","volume":"371","author":"Byrd","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaccao.2023.09.002_bib41","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1158\/1078-0432.CCR-19-2856","article-title":"Ibrutinib treatment for first-line and relapsed\/refractory chronic lymphocytic leukemia: final analysis of the pivotal phase Ib\/II PCYC-1102 study","volume":"26","author":"Byrd","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jaccao.2023.09.002_bib42","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0211228","article-title":"Ibrutinib increases the risk of hypertension and atrial fibrillation: systematic review and meta-analysis","volume":"14","author":"Caldeira","year":"2019","journal-title":"PloS One"},{"key":"10.1016\/j.jaccao.2023.09.002_bib43","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1136\/heartjnl-2021-319110","article-title":"Association between ibrutinib treatment and hypertension","volume":"108","author":"Lee","year":"2022","journal-title":"Heart"},{"key":"10.1016\/j.jaccao.2023.09.002_bib44","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.16326","article-title":"Hypertension in patients treated with ibrutinib for chronic lymphocytic leukemia","volume":"2","author":"Roeker","year":"2019","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jaccao.2023.09.002_bib45","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1158\/2159-8290.CD-19-1130","article-title":"Acalabrutinib plus obinutuzumab in treatment-na\u00efve and relapsed\/refractory chronic lymphocytic leukemia","volume":"10","author":"Woyach","year":"2020","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jaccao.2023.09.002_bib46","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1056\/NEJMoa1314583","article-title":"PI3K\u03b4 inhibition by idelalisib in patients with relapsed indolent lymphoma","volume":"370","author":"Gopal","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaccao.2023.09.002_bib47","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa1315226","article-title":"Idelalisib and rituximab in relapsed chronic lymphocytic leukemia","volume":"370","author":"Furman","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaccao.2023.09.002_bib48","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1057385","article-title":"Ibrutinib enhances IL-17 response by modulating the function of bone marrow derived dendritic cells","volume":"5","author":"Natarajan","year":"2016","journal-title":"OncoImmunology"},{"key":"10.1016\/j.jaccao.2023.09.002_bib49","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1002\/ajh.25638","article-title":"Final analysis from RESONATE: up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma","volume":"94","author":"Munir","year":"2019","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jaccao.2023.09.002_bib50","doi-asserted-by":"crossref","first-page":"3440","DOI":"10.1182\/bloodadvances.2021006434","article-title":"Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia","volume":"6","author":"Barr","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.jaccao.2023.09.002_bib51","doi-asserted-by":"crossref","first-page":"3453","DOI":"10.1200\/JCO.21.00693","article-title":"Cardiovascular risk associated with ibrutinib use in chronic lymphocytic leukemia: a population-based cohort study","volume":"39","author":"Abdel-Qadir","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jaccao.2023.09.002_bib52","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1016\/j.jacc.2019.07.056","article-title":"Cardiovascular toxicities associated with ibrutinib","volume":"74","author":"Salem","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jaccao.2023.09.002_bib53","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1161\/CIRCULATIONAHA.108.776831","article-title":"Mechanisms of cardiac dysfunction associated with tyrosine kinase inhibitor cancer therapeutics","volume":"118","author":"Chen","year":"2008","journal-title":"Circulation"},{"issue":"17","key":"10.1016\/j.jaccao.2023.09.002_bib54","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jaccao.2023.09.002_bib55","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1056\/NEJMoa1817073","article-title":"Ibrutinib-rituximab or chemoimmunotherapy for chronic lymphocytic leukemia","volume":"381","author":"Shanafelt","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaccao.2023.09.002_bib56","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.580622","article-title":"Risk of bleeding associated with ibrutinib in patients with B-cell malignancies: a systematic review and meta-analysis of randomized controlled trials","volume":"11","author":"Wang","year":"2020","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jaccao.2023.09.002_bib57","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.clml.2018.06.016","article-title":"Safety analysis of four randomized controlled studies of ibrutinib in patients with chronic lymphocytic leukemia\/small lymphocytic lymphoma or mantle cell lymphoma","volume":"18","author":"O\u2019Brien","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.jaccao.2023.09.002_bib58","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.3324\/haematol.2015.126672","article-title":"Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib","volume":"100","author":"Lipsky","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.jaccao.2023.09.002_bib59","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.3229.3229","article-title":"Major bleeding with ibrutinib: more than expected","volume":"128","author":"Kunk","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.jaccao.2023.09.002_bib60","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.clml.2018.07.287","article-title":"Risk of major bleeding with ibrutinib","volume":"18","author":"Mock","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"2","key":"10.1016\/j.jaccao.2023.09.002_bib61","doi-asserted-by":"crossref","first-page":"e31","DOI":"10.1111\/bjh.16422","article-title":"The risk of bleeding in patients receiving ibrutinib combined with novel direct oral anticoagulants","volume":"189","author":"Raz","year":"2020","journal-title":"Br J Haematol"},{"issue":"7","key":"10.1016\/j.jaccao.2023.09.002_bib62","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1038\/s41375-023-01869-1","article-title":"Evaluation of bleeding events in patients receiving acalabrutinib therapy","volume":"37","author":"Kumar","year":"2023","journal-title":"Leukemia"},{"key":"10.1016\/j.jaccao.2023.09.002_bib63","doi-asserted-by":"crossref","first-page":"3592","DOI":"10.1182\/blood-2003-04-1142","article-title":"Tec regulates platelet activation by GPVI in the absence of Btk","volume":"102","author":"Atkinson","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.jaccao.2023.09.002_bib64","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1172\/JCI122955","article-title":"Functional significance of the platelet immune receptors GPVI and CLEC-2","volume":"129","author":"Rayes","year":"2019","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jaccao.2023.09.002_bib65","doi-asserted-by":"crossref","first-page":"C902","DOI":"10.1152\/ajpcell.00296.2020","article-title":"Assessment of the effects of Syk and BTK inhibitors on GPVI-mediated platelet signaling and function","volume":"320","author":"Zheng","year":"2021","journal-title":"Am J Physiol Cell Physiol"},{"key":"10.1016\/j.jaccao.2023.09.002_bib66","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1038\/leu.2014.247","article-title":"Ibrutinib inhibits collagen-mediated but not ADP-mediated platelet aggregation","volume":"29","author":"Kamel","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.jaccao.2023.09.002_bib67","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2021-148719","article-title":"Evaluation of the incidence and risk factors associated with bleeding events in patients receiving acalabrutinib therapy","volume":"138","author":"Kumar","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jaccao.2023.09.002_bib68","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1182\/hematology.2020000118","article-title":"Managing toxicities of Bruton tyrosine kinase inhibitors","volume":"2020","author":"Lipsky","year":"2020","journal-title":"Hematology"},{"key":"10.1016\/j.jaccao.2023.09.002_bib69","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1002\/hon.2503","article-title":"Practical management of ibrutinib in the real life: Focus on atrial fibrillation and bleeding","volume":"36","author":"Boriani","year":"2018","journal-title":"Hematol Onc"},{"key":"10.1016\/j.jaccao.2023.09.002_bib70","first-page":"233","article-title":"Ibrutinib is associated with increased cardiovascular events and major bleeding in older CLL patients","volume":"5","author":"Diamond","year":"2023","journal-title":"J\u00a0Am Coll Cardiol CardioOnc"},{"key":"10.1016\/j.jaccao.2023.09.002_bib71","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2020.106432","article-title":"Ibrutinib restores immune cell numbers and function in first-line and relapsed\/refractory chronic lymphocytic leukemia","volume":"97","author":"Solman","year":"2020","journal-title":"Leukemia Res"},{"key":"10.1016\/j.jaccao.2023.09.002_bib72","first-page":"52","article-title":"2021 guideline for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline from the American Heart Association\/American Stroke Association","author":"Kleindorfer","year":"2021","journal-title":"Stroke"},{"key":"10.1016\/j.jaccao.2023.09.002_bib73","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jacc.2019.01.011","article-title":"2019 AHA\/ACC\/HRS focused update of the 2014 AHA\/ACC\/HRS Guideline for the Management of Patients With Atrial Fibrillation","volume":"74","author":"January","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jaccao.2023.09.002_bib74","doi-asserted-by":"crossref","first-page":"IJH31","DOI":"10.2217\/ijh-2020-0010","article-title":"Venetoclax: a real game changer in treatment of chronic lymphocytic leukemia","volume":"9","author":"Molica","year":"2020","journal-title":"Int J Hematol Oncol"},{"key":"10.1016\/j.jaccao.2023.09.002_bib75","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1182\/blood.2021014488","article-title":"Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort","volume":"139","author":"Tam","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.jaccao.2023.09.002_bib76","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2021-149919","article-title":"Venetoclax consolidation in patients with high-risk CLL who have been on ibrutinib more than a year achieves a high rate of undetectable minimal residual disease","volume":"138","author":"Thompson","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jaccao.2023.09.002_bib77","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s13045-022-01295-3","article-title":"Clinical experiences with venetoclax and other pro-apoptotic agents in lymphoid malignancies: lessons from monotherapy and chemotherapy combination","volume":"15","author":"Lew","year":"2022","journal-title":"J\u00a0Hematol Oncol"},{"key":"10.1016\/j.jaccao.2023.09.002_bib78","doi-asserted-by":"crossref","first-page":"4371","DOI":"10.1158\/1078-0432.CCR-17-3761","article-title":"Comprehensive safety analysis of venetoclax monotherapy for patients with relapsed\/refractory chronic lymphocytic leukemia","volume":"24","author":"Davids","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jaccao.2023.09.002_bib79","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1056\/NEJMoa1713976","article-title":"Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia","volume":"378","author":"Seymour","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaccao.2023.09.002_bib80","doi-asserted-by":"crossref","first-page":"4042","DOI":"10.1200\/JCO.20.00948","article-title":"Venetoclax plus rituximab in relapsed chronic lymphocytic leukemia: 4-year results and evaluation of impact of genomic complexity and gene mutations from the MURANO Phase III study","volume":"38","author":"Kater","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jaccao.2023.09.002_bib81","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/S1470-2045(20)30443-5","article-title":"Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial","volume":"21","author":"Al-Sawaf","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jaccao.2023.09.002_bib82","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1056\/NEJMoa1815281","article-title":"Venetoclax and obinutuzumab in patients with CLL and coexisting conditions","volume":"380","author":"Fischer","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaccao.2023.09.002_bib83","article-title":"Abstract 11835: evaluation of cardiovascular adverse events associated with ibrutinib, venetoclax and idelalisib used in treatment of chronic lymphocytic leukemia","volume":"138","author":"Mahida","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.jaccao.2023.09.002_bib84","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.3324\/haematol.2020.272500","article-title":"Phase II study of acalabrutinib in ibrutinib-intolerant patients with relapsed\/refractory chronic lymphocytic leukemia","volume":"106","author":"Rogers","year":"2021","journal-title":"Haematol"},{"key":"10.1016\/j.jaccao.2023.09.002_bib85","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1182\/bloodadvances.2018030007","article-title":"Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib","volume":"3","author":"Awan","year":"2019","journal-title":"Blood Adv"}],"container-title":["JACC: CardioOncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666087323002594?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666087323002594?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T18:56:44Z","timestamp":1762973804000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666087323002594"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":84,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["S2666087323002594"],"URL":"https:\/\/doi.org\/10.1016\/j.jaccao.2023.09.002","relation":{},"ISSN":["2666-0873"],"issn-type":[{"value":"2666-0873","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cardiovascular Toxicities of BTK\u00a0Inhibitors in Chronic Lymphocytic\u00a0Leukemia","name":"articletitle","label":"Article Title"},{"value":"JACC: CardioOncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaccao.2023.09.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}]}}